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listed in the table below. All analyses were adjusted for
donor/recipient age, sex, CMV status, HLA mismatch,
CD34+ cells, regimen intensity and relapse risk.
There were 191 pts in the sibling donor (SD) group and
190 pts in the unrelated donor (UD) group respectively.
The median age of pts and donors in the SD group was
older (P < .05). Pts in UD group received a higher median
of CD 34+cell dose (7.31 vs.5.63 x 106/kg P  .0001).
Median follow up of surviving pts in both groups was 58.3
months. More pts had ALC 30>400x 106 (75 vs. 65% P ¼
.025) and more pts survived (47 vs.36%P ¼ .038) in the SD
group. Factors associated with lower ALC 30 were: higher
donor age, HLA mismatch, lower recipient age, and lower
CD34 cell dose.
Lower ALC 30 (400x 106/L) was associated with lower
OS, and increased non relapse mortality (NRM) for the whole
cohort as well as for the SD and UD groups separately. Lower
ALC 30 was associated with more severe aGVHD (III-IV) in
the UD group. Lower ALC 30 was associated with more CMV
reactivation and a trend towards more aGVHD in the SD
group.
Conclusion: In this large retrospective study using Tac/MMF
for GVHD prophylaxis ALC 30 400 x 106/L was associated
with worse OS, increased NRM and aGVHD.Hazard Ratios of ALC 30 with various event outcomes
Combined Related Unrelated
Mortality
HR 2.29*** 2.58*** 2.23**
CI 1.68-3.13 1.61-4.13 1.44-3.46
NRM
HR 3.03*** 3.19*** 3.1***
CI 2.08-4.43 1.75-5.80 1.84-5.23
aGVHD (II-IV)
HR 1.47* 1.64 1.43
CI 1.06-2.03 0.99-2.72 0.9-2.28
aGVHD (III-IV)
HR 1.97** 1.9 2.19**
CI 1.31-2.97 0.96-3.75 1.27-3.77
cGVHD
HR 1.01 0.83 1.02
CI 0.7-1.45 0.47-1.47 0.62-1.69
CMV
HR 1.13 1.99* 0.6
CI 0.71-1.81 1.05-3.75 0.27-1.29
Relapse
HR 1.196 1.4 1.03
CI 0.69-2.06 0.65-2.99 0.45-2.34
* P-value < .05.
** P-value < .01.
*** P-value < .001.174
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Introduction: Lymphocyte recovery after T cell depleted
allogeneic stem cell transplant (allo-HCT) is delayed for at
least 6-9 months, particularly after alemtuzumab (AL)
administration. Most studies predominantly involving
matched sibling donors and T cell replete allo-HCT have
shown that early lymphocyte recovery by day 30 is associ-
ated with better OS and EFS. Impact of absolute lymphocyte
count (ALC) after AL based allo-HCT using unrelated donors
(UD) is unknown.
Methods: We retrospectively evaluated 30 consecutive
patients (pts) who underwent allo-HCT from UDs at
Markey Cancer Center between January 2010 and May
2012. The primary end point of the study was to evaluate
the impact of ALC on transplant outcomes and assess any
predictors of higher ALC. Cox proportional hazards model
was used for time to event analysis and Odds Ratios were
calculated using logistic regression to evaluate for
predictors for ALC  300 at day 90. AL dose used was 60
mg (20 mg daily x 3 days). Low relapse risk was deﬁned
as AML and ALL in CR1, MDS with less than 10% blasts,
CLL/NHL/HL with PR and or <5 cm lymphadenopathy and
CML in chronic phase.
Results: Median age of the pts was 53.5 yrs (20-67).
Patients had AML (12), MDS (4), ALL (5), CLL (4), CML (2)
NHL (1), Hodgkins disease (1) and Aplastic Anemia (1). All
Pretransplant conditioning included alemtuzumab plus
Cyclophosphamide (Cy) TBI for 9 pts, Busulfan (Bu)/Cy for
8 pts and ﬂudarabine (Flu)/Melphalan (Mel) for 13 pts.
Seventeen pts had female donors, and 15 pts had donors
seropositive for CMV. Source of stem cells was bone
marrow (BM) for 16 pts and peripherally mobilized stem
cells (PBSCs) for 14 pts. Median CD 34+ cells infused were
4.05 x 106 cells/kg (0.83-12.98). Twenty four pts had high
relapse risk.
At day 90 ALC <300 x 106/ml was associated with higher
mortality (HR¼4.65, P ¼ .03). In our study, ALC 90 was not
associated with GVHD, NRM, CMV reactivation or relapse.
ALC 90 >300 x 106/ml was also not associated with donor's
sex, CMV status, pt's age, sex, CMV status, CD 34 cells infused,
relapse risk, HLA mismatch, source of stem cells or type of
conditioning regimen.
After a median follow up of 431 days (118-909), 16
patients are alive. Causes of deathwere GVHD (6), relapse (2),
graft failure (2), infection (2), VOD (1) and hemorrhage (1).
Five pts have relapsed. Cumulative incidence of aGVHD (II-
IV) was 36.7%, cGVHD (mild, moderate) 13.3% and CMV
reactivation (46.7%).
Conclusion: AL is associated with delayed recovery of ALC
post allo-HCT. ALC 90  300 x 106/ml was associated with
four fold higher hazard of death after AL as compared to
patients with ALC 90 > 300 x 106/ml at any given time.
Further studies are needed to conﬁrm our preliminary
ﬁndings, to elucidate factors associated with higher ALC90,
and ultimately to test proposed interventions to improve
ALC90 after allo-HCT.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210S200175
Immune Reconstitution Following Reduced Intensity
Stem Cell Transplantation for Non-Malignant Disorders
in Children
Jeffrey J. Bednarski II 1, Catherine Le 2, Lisa Murray 3,
Robert Hayashi 4, Lolie Yu 5, Jignesh Dalal 6, Naynesh Kamani 7,
David A. Jacobsohn 8, Michael A. Pulsipher 9,
Aleksandra Petrovic 10, Ka Wah Chan 11, Michael Grimley 12,
Paul Haut 13, Roberta Adams 14, Dorothea Douglas 15,
Sonali Chaudhury 16, Andrew Gilman 17, Jennifer Jaroscak 18,
Martin Andreansky 19, Kirk R. Schultz 20, Jennifer R Willert 21,
Shalini Shenoy 22. 1Washington University School of Medicine,
St. Louis, MO; 2Washington University School of Medicine, St.
Louis, MO; 3 Pediatric Hematology/ Oncology, Washington
University, St. Louis, MO; 4Dept of Pediatrics, St. Louis
Children's Hospital, St. Louis, MO; 5 Pediatric Hematology-
Oncology, Children's Hospital/LSUHSC New Orleans,
NewOrleans, LA; 6 BMT, Children's Mercy Hospital, Kansas City,
MO; 7 Children's National Medical Center, Washington, DC;
8 Division of Stem Cell Transplantation, Children's National
Medical Center, Washington, DC; 9 Division of Hematology and
Hematologic Malignancies, Primary Children's Medical Center/
Huntsman Cancer Institute, University of Utah School of
Medicine, Salt Lake City, UT; 10 All Children's Hospital, St.
Petersburg, FL; 11 Pediatric Blood and Marrow Stem Cell
Transplant, Texas Transplant Institute, San Antonio, TX; 12 Texas
Transplant Institute, San Antonio, TX; 13 Pediatric Hematology/
Oncology, Riley Hospital for Children/Indiana University,
Indianapolis, IN; 14 BMT Internal Medicine, Mayo Hospital,
Phoenix, AZ; 15 BMT, Phoenix Childrens Hospital, Phoenix, AZ;
16Hematology/Oncology/Stem Cell Transplantation,
Hematology/Oncology/Stem Cell Transplantation, Chicago, IL;
17 Levine's Children Hospital, Charlotte, NC; 18 UNC-CHapel Hill,
Durham, NC, United States of America; 19 University of Miami
Miller School of Medicine, Miami, FL; 20 Pediatric Hematology/
Oncology/BMT, BC Children's Hospital/UBC, Vancouver, BC,
Canada; 21 Children's Hosp San Diego, San Diego, CA;
22Washington University in St. Louis, St. Louis, MOIntroduction: Myeloablative stem cell transplants (SCT) for
nonmalignant disorders (NMD) are complicated by early and
late treatment-related toxicities. We used a novel reduced
intensity conditioning (RIC) regimen with early administra-
tion of alemtuzumab to achieve donor engraftment with
lower toxicities in NMD. Delayed immune reconstitution (IR)
and severe/fatal late infections have been previously
described with RIC using alemtuzumab peri-SCT. Early
administration in our protocol is designed to selectively
deplete host immunity with minimal effects on post-trans-
plant IR.We report the kinetics of IR and infection patterns in
the ﬁrst year post-SCT with this approach.
Methods: HSCT was performed for marrow failure, genetic
diseases or immune disorders with alemtuzumab (day -22
to -19; 33 mg if < 10 kg; 48 mg if > 10 kg), ﬂudarabine (day
-8 to -4; 150 mg/m2), and melphalan (day -3; 140 mg/m2)
followed by infusion of matched related (MRD) or matched
unrelated (MUD) marrow/PBSC. GVHD prophylaxis included
a calcineurin inhibitor (6-9 m), short course methotrexate
(days 1, 3 and 6) and short course prednisone (28 d). Stable
engraftment (> 20% donor) occurred in 89% of patients.
Lymphocyte numbers, proliferation, and immunoglobulin
levels were measured at 3, 6 and 12 m. We evaluated 35
MRD and 31 MUD recipients with immune studies collected
at a minimum of two time periods after SCT and tracked
cumulative incidence of bacterial, viral and fungal
infections.
Results: Lymphocyte, NK, CD4 and CD8 T cell numbers and
immunoglobulin levels normalized by 6 months post SCT in
both groups. MUD SCT resulted in slower IR than MRD.
Notably, MUD recipients had lower B cells after 6 months
though immunoglobulin levels were normal. The kinetics of
recovery of immune function correlated with incidence of
infections, which were highest until day 100 and declined
after day 180.
Conclusions: SCT following RIC with early administration of
alemtuzumab resulted in successful donor marrow
engraftment and rapid IR within 6 months in contrast to
previous experience. Only B cell recovery was noted to be
slower in MUD compared to MRD transplants. This RIC
regimen supports early immune recovery with reduced
and more localized infectious complications after the ﬁrst
6 months. These results provide a context for reﬁning
infection surveillance, antibiotic prophylaxis, revaccination
and return to normal lifestyle devoid of infectious
complications.176
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Early lymphocyte recovery has shown to be associated
with superior survival in patients with hematological
malignancies following umanipulated haploidentical blood
and marrow transplantion (HBMT), but its effect on clinical
outcomes in patients with myelodysplastic syndrome (MDS)
and acute myeloid leukemia (AML) evolving from MDS is
